Hypoxia and intra-complex genetic suppressors rescue complex I mutants by a shared mechanism.
C. elegans
NADH:ubiquinone oxidoreductase
NDUFA6
NDUFS4
complex I
electron transport chain
hyperoxia
hypoxia
mitochondria
oxygen
Journal
Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066
Informations de publication
Date de publication:
05 Jan 2024
05 Jan 2024
Historique:
received:
20
02
2023
revised:
09
09
2023
accepted:
05
12
2023
medline:
13
1
2024
pubmed:
13
1
2024
entrez:
12
1
2024
Statut:
aheadofprint
Résumé
The electron transport chain (ETC) of mitochondria, bacteria, and archaea couples electron flow to proton pumping and is adapted to diverse oxygen environments. Remarkably, in mice, neurological disease due to ETC complex I dysfunction is rescued by hypoxia through unknown mechanisms. Here, we show that hypoxia rescue and hyperoxia sensitivity of complex I deficiency are evolutionarily conserved to C. elegans and are specific to mutants that compromise the electron-conducting matrix arm. We show that hypoxia rescue does not involve the hypoxia-inducible factor pathway or attenuation of reactive oxygen species. To discover the mechanism, we use C. elegans genetic screens to identify suppressor mutations in the complex I accessory subunit NDUFA6/nuo-3 that phenocopy hypoxia rescue. We show that NDUFA6/nuo-3(G60D) or hypoxia directly restores complex I forward activity, with downstream rescue of ETC flux and, in some cases, complex I levels. Additional screens identify residues within the ubiquinone binding pocket as being required for the rescue by NDUFA6/nuo-3(G60D) or hypoxia. This reveals oxygen-sensitive coupling between an accessory subunit and the quinone binding pocket of complex I that can restore forward activity in the same manner as hypoxia.
Identifiants
pubmed: 38215760
pii: S0092-8674(23)01342-9
doi: 10.1016/j.cell.2023.12.010
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests V.K.M. is listed as an inventor on patents filed by MGH on therapeutic uses of hypoxia. V.K.M. is a paid advisor to 5am Ventures. O.S.S. was a paid consultant for Proteinaceous, Inc. V.K.M. is on the Advisory Board at Cell.